Q4 2024 Brainstorm Cell Therapeutics Inc Earnings Call Transcript
Key Points
- Brainstorm Cell Therapeutics Inc (BCLI) has secured a special protocol assessment with the FDA, significantly de-risking the regulatory pathway for their NurOwn technology.
- The company is actively negotiating clinical trial agreements with approximately 15 leading clinical centers across the United States, indicating strong interest from renowned ALS clinicians and researchers.
- Brainstorm Cell Therapeutics Inc (BCLI) has partnered with IQVIA, a leading clinical research organization, to ensure efficient execution of their Phase 3b trial.
- The company has contracted with Pluri Inc. for clinical manufacturing, leveraging their expertise in GMP-compliant production, and plans to bring an additional US-based manufacturing center online.
- Brainstorm Cell Therapeutics Inc (BCLI) is exploring multiple funding avenues, including licensing non-core assets and non-dilutive financing opportunities such as grants, to secure necessary funding for the Phase 3b trial.
- The company is facing financial constraints, with cash, cash equivalents, and restricted cash at approximately $0.4 million as of the end of December 2024.
- There are perceived delays in initiating the Phase 3b trial due to the intricate and time-consuming nature of regulatory processes and negotiations with clinical trial sites.
- Brainstorm Cell Therapeutics Inc (BCLI) anticipates needing approximately $20 million to $30 million annually to see the trial to its conclusion, which is challenging given the current market conditions for non-revenue biotech companies.
- The company has implemented salary reductions and periods of unpaid work for its staff to manage financial constraints, indicating significant financial pressure.
- Skepticism remains among analysts and investors regarding the efficacy of NurOwn, despite the company's efforts to address these concerns through trial design and collaboration with key opinion leaders.
Good morning, everyone, and welcome to BrainStorm Cell Therapeutics' fourth-quarter 2024 earnings call. (Operator Instructions) Please note this conference is being recorded.
I will now turn the conference over to your host, Michael Wood. Michael, the floor is yours.
Thank you, operator. Good morning and thank you for joining us. Before passing it off to company management for prepared remarks, I'd like to remind listeners on this conference call that it will contain numerous statements, descriptions, forecasts, and projections regarding BrainStorm Cell Therapeutics and its potential future business operations and performance statements regarding the market potential of the treatment for neurodegenerative disorders such as ALS, the sufficiency of the company's existing capital resources for continuing operations in 2025 and beyond, the safety and clinical effectiveness of the NurOwn technology platform, clinical trials of NurOwn and related clinical development programs, and the company's ability to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
